Windtree Therapeutics (WINT) has received a non-binding letter of intent to purchase its preclinical oncology aPKCi inhibitor platform for $7M dollars up front in cash or freely tradable stock and up to $130 in milestone payments and high, single digit royalties up to $1.5B. he agreement also includes options with additional consideratiMon to acquire the Company’s cardiovascular clinical and preclinical stage drug candidates and its agreement to act as the manufacturing agent for Evofem Biosciences for its FDA approved product. As part of the agreement, the Company has 21 days to close the oncology aPKCi portion of the transaction.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WINT:
- Windtree Therapeutics announces agreement to acquire Titan Environmental
- Windtree Therapeutics announces plan for cryptocurrency treasury policy
- Windtree says interim results for SEISMiC SCAI Stage C study set for July 2025
- Windtree Therapeutics Inc. Reports Q1 2025 Financial Results
- Windtree Therapeutics files to sell 42.17M shares of common stock for holders